Projects funded by the NCN

Canonical and non-canonical roles of DDK in oncogenesis: a cornerstone for the development of novel, potent anticancer t...

Call: SONATA BIS 14 , Panel: NZ3

Principal investigator: dr Jan Marian Suski

Międzynarodowy Instytut Mechanizmów i Maszyn Molekularnych Polskiej Akademii Nauk

Precision double strike against non-small cell lung cancer. Insights into multidirectional therapies and the landscape o...

Call: OPUS 27 , Panel: NZ5

Principal investigator: dr Katarzyna Anna Malarz

Politechnika Śląska

Integrated multi-omics approach to accelerate anticancer drug discovery by targeting metabolic reprogramming in human co...

Call: OPUS 26 , Panel: NZ7

Principal investigator: dr hab. Danuta Dudzik

Gdański Uniwersytet Medyczny, Wydział Farmaceutyczny

Identification of potential markers aiming early diagnostics of progression and tailoring metastasis-oriented therapies ...

Call: OPUS 20 , Panel: NZ5

Principal investigator: dr Natalia Bednarz-Knoll

Gdański Uniwersytet Medyczny, Międzyuczelniany Wydział Biotechnologii Uniwersytetu Gdańskiego i Gdańskiego Uniwersytetu Medycznego

The role of MCPIP1 as a potential tumor suppressor during development and treatment of clear cell renal cell carcinoma

Call: PRELUDIUM 13 , Panel: NZ5

Principal investigator: dr Paulina Marona

Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

Molecular background of brain metastases in lung cancer

Call: SONATA 12 , Panel: NZ2

Principal investigator: dr Marcin Nicoś

Uniwersytet Medyczny w Lublinie, Wydział Lekarski

Nanotheranostics dedicated to targeted anticancer therapies: Novel magnetic hybrid carbon-based materials - synthesis an...

Call: PRELUDIUM 11 , Panel: ST5

Principal investigator: Artur Kasprzak

Politechnika Warszawska, Wydział Chemiczny

Significance of PIM-1 kinase mutations in progression of chronic lymphocytic leukemia

Call: SONATA 11 , Panel: NZ5

Principal investigator: dr Bartosz Puła

Instytut Hematologii i Transfuzjologii

Evaluation of peroxiredoxins 1 and 2 along with the thioredoxin-thioredoxin reductase system as new therapeutic targets ...

Call: OPUS 4 , Panel: NZ7

Principal investigator: dr hab. Radosław Zagożdżon

Warszawski Uniwersytet Medyczny, I Wydział Lekarski

PIM kinases as rational therapeutic targets in lymphoid malignancies.

Call: OPUS 2 , Panel: NZ4

Principal investigator: dr hab. Przemysław Juszczyński

Instytut Hematologii i Transfuzjologii